These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 33451980)

  • 1. A MET Targeting Antibody-Drug Conjugate Overcomes Gemcitabine Resistance in Pancreatic Cancer.
    Cazes A; Betancourt O; Esparza E; Mose ES; Jaquish D; Wong E; Wascher AA; Tiriac H; Gymnopoulos M; Lowy AM
    Clin Cancer Res; 2021 Apr; 27(7):2100-2110. PubMed ID: 33451980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors.
    Gymnopoulos M; Betancourt O; Blot V; Fujita R; Galvan D; Lieuw V; Nguyen S; Snedden J; Stewart C; Villicana J; Wojciak J; Wong E; Pardo R; Patel N; D'Hooge F; Vijayakrishnan B; Barry C; Hartley JA; Howard PW; Newman R; Coronella J
    Mol Oncol; 2020 Jan; 14(1):54-68. PubMed ID: 31736230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model.
    Brandes F; Schmidt K; Wagner C; Redekopf J; Schlitt HJ; Geissler EK; Lang SA
    BMC Cancer; 2015 Feb; 15():71. PubMed ID: 25884642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
    Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
    Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer.
    Hage C; Rausch V; Giese N; Giese T; Schönsiegel F; Labsch S; Nwaeburu C; Mattern J; Gladkich J; Herr I
    Cell Death Dis; 2013 May; 4(5):e627. PubMed ID: 23661005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer.
    Burkhart C; Fleyshman D; Kohrn R; Commane M; Garrigan J; Kurbatov V; Toshkov I; Ramachandran R; Martello L; Gurova KV
    Oncotarget; 2014 Nov; 5(22):11038-53. PubMed ID: 25402820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-κB activation.
    Ju HQ; Li H; Tian T; Lu YX; Bai L; Chen LZ; Sheng H; Mo HY; Zeng JB; Deng W; Chiao PJ; Xu RH
    J Pineal Res; 2016 Jan; 60(1):27-38. PubMed ID: 26445000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumor activity of antibody drug conjugate targeting aspartate-β-hydroxylase in pancreatic ductal adenocarcinoma.
    Nagaoka K; Bai X; Ogawa K; Dong X; Zhang S; Zhou Y; Carlson RI; Jiang ZG; Fuller S; Lebowitz MS; Ghanbari H; Wands JR
    Cancer Lett; 2019 May; 449():87-98. PubMed ID: 30768955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical Efficacy of Anti-RON Antibody-Drug Conjugate Zt/g4-MMAE for Targeted Therapy of Pancreatic Cancer Overexpressing RON Receptor Tyrosine Kinase.
    Yao HP; Feng L; Weng TH; Hu CY; Suthe SR; Mostofa AGM; Chen LH; Wu ZG; Wang WL; Wang MH
    Mol Pharm; 2018 Aug; 15(8):3260-3271. PubMed ID: 29944378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Difluoromethylornithine Combined with a Polyamine Transport Inhibitor Is Effective against Gemcitabine Resistant Pancreatic Cancer.
    Gitto SB; Pandey V; Oyer JL; Copik AJ; Hogan FC; Phanstiel O; Altomare DA
    Mol Pharm; 2018 Feb; 15(2):369-376. PubMed ID: 29299930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Xenografts Derived From Patients' Ascites Recapitulate the Gemcitabine Resistance Observed in Pancreatic Cancer Patients.
    Machinaga A; Hori Y; Shimizu K; Okahara K; Yanagita E; Miyoshi M; Itoh T; Sasai K
    Pancreas; 2019; 48(10):1294-1302. PubMed ID: 31688592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glypican-1 Is a Novel Target for Stroma and Tumor Cell Dual-Targeting Antibody-Drug Conjugates in Pancreatic Cancer.
    Tsujii S; Serada S; Fujimoto M; Uemura S; Namikawa T; Nomura T; Murakami I; Hanazaki K; Naka T
    Mol Cancer Ther; 2021 Dec; 20(12):2495-2505. PubMed ID: 34583978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo.
    DeRosier LC; Huang ZQ; Sellers JC; Buchsbaum DJ; Vickers SM
    J Gastrointest Surg; 2006 Nov; 10(9):1291-300; discussion 1300. PubMed ID: 17114015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multimodal Treatment Eliminates Cancer Stem Cells and Leads to Long-Term Survival in Primary Human Pancreatic Cancer Tissue Xenografts.
    Hermann PC; Trabulo SM; Sainz B; Balic A; Garcia E; Hahn SA; Vandana M; Sahoo SK; Tunici P; Bakker A; Hidalgo M; Heeschen C
    PLoS One; 2013; 8(6):e66371. PubMed ID: 23825539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer.
    Kang YW; Lee JE; Jung KH; Son MK; Shin SM; Kim SJ; Fang Z; Yan HH; Park JH; Han B; Cheon MJ; Woo MG; Lim JH; Kim YS; Hong SS
    Cancer Lett; 2018 Dec; 438():174-186. PubMed ID: 30217561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic nicotine inhibits the therapeutic effects of gemcitabine on pancreatic cancer in vitro and in mouse xenografts.
    Banerjee J; Al-Wadei HA; Schuller HM
    Eur J Cancer; 2013 Mar; 49(5):1152-8. PubMed ID: 23146955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SHR-A1403, a novel c-Met antibody-drug conjugate, exerts encouraging anti-tumor activity in c-Met-overexpressing models.
    Yang CY; Wang L; Sun X; Tang M; Quan HT; Zhang LS; Lou LG; Gou SH
    Acta Pharmacol Sin; 2019 Jul; 40(7):971-979. PubMed ID: 30643210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy.
    Yao HP; Feng L; Suthe SR; Chen LH; Weng TH; Hu CY; Jun ES; Wu ZG; Wang WL; Kim SC; Tong XM; Wang MH
    J Immunother Cancer; 2019 Mar; 7(1):75. PubMed ID: 30871619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of metformin's anti‑tumor activity against gemcitabine‑resistant pancreatic adenocarcinoma.
    Suzuki K; Takeuchi O; Suzuki Y; Kitagawa Y
    Int J Oncol; 2019 Feb; 54(2):764-772. PubMed ID: 30570108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts.
    Lohse I; Borgida A; Cao P; Cheung M; Pintilie M; Bianco T; Holter S; Ibrahimov E; Kumareswaran R; Bristow RG; Tsao MS; Gallinger S; Hedley DW
    Br J Cancer; 2015 Jul; 113(3):425-32. PubMed ID: 26180923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.